PMID: 16507399Mar 2, 2006Paper

Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
S R Olsen

Abstract

The taxanes paclitaxel and docetaxel are widely used antineoplastic agents that have demonstrated significant clinical activity against a number of human tumor types. Taxanes promote microtubule polymerization and stabilization which inhibits mitosis and leads to apoptosis. Taxanes induce a number of other molecular pathways. One such example is their ability to promote transcription of the cyclo-oxygenase (COX)-2 gene and to stabilize the COX-2 messenger RNA transcript. This leads to increased production of prostaglandins, which have been implicated in tumorigenesis. Increased COX-2 activity has been associated with tumor growth, poor prognostic characteristics, and unfavorable clinical outcome; therefore, up-regulation of COX-2 might attenuate the anti-tumor effect of the taxanes. This provides the rationale for the use of COX-2 inhibitors in combination with taxanes, as this could theoretically improve the clinical efficacy of paclitaxel and docetaxel. Results from preclinical studies have generally shown enhanced anticancer activity from the addition of COX-2 inhibitors to taxane treatment. Data from Phase II clinical studies in patients with non-small cell lung cancer (NSCLC) have suggested a marginal improvement in respon...Continue Reading

References

Jun 30, 2000·The New England Journal of Medicine·G SteinbachG Kelloff
Mar 30, 2001·The Journal of Biological Chemistry·H ShengR N DuBois
Apr 26, 2001·The Journal of Biological Chemistry·M DohadwalaS M Dubinett
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford

❮ Previous
Next ❯

Citations

Jun 3, 2011·Archivum Immunologiae Et Therapiae Experimentalis·Toru Akiyama, Sakae Tanaka
Feb 8, 2013·Angiogenesis·Guido BocciRomano Danesi
Dec 31, 2009·Investigational New Drugs·Binbing LingJian Yang
Apr 9, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Devender S DhandaUday B Kompella
Nov 19, 2011·Biochemical and Biophysical Research Communications·Lixin SunLuyong Zhang
May 22, 2009·Clinical and Experimental Dermatology·S NakamuraH Iizuka
Mar 25, 2011·Expert Opinion on Drug Safety·Anneleen LintermansRobert Paridaens
Dec 28, 2010·European Journal of Pharmacology·Tomoyuki NakanoIchiro Wakabayashi
May 2, 2014·Frontiers in Oncology·Prabhat Singh MalikNicolas André
Feb 23, 2019·PloS One·Ricardo LageIsabel Moscoso
Jul 28, 2019·Cancers·Laurie G HudsonAngela Wandinger-Ness
Dec 7, 2013·Archives of Disease in Childhood·Yi-Chia KuChia-Hung Kao
Nov 26, 2009·Molecular Cancer Therapeutics·Toru AkiyamaPeter F M Choong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis